Related Experiment Video
Updated: Mar 3, 2026
A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
Published on: July 3, 2013
Characterization of the Indirubin Derivative LDD970 as a Small Molecule Aurora Kinase A Inhibitor in Human Colorectal
Karyn Muzinga Ndolo1, Kyeong Ryang Park1, Hyo Jeong Lee1
1College of Pharmacy and Research Institute of Pharmaceutical Sciences, Gyeongsang National University, Jinju 52828, Korea.
Abstract:
Aurora kinase A plays an essential role in mitosis including chromosome separation and cytokinesis. Aberrant expression and activity of Aurora kinase A is associated with numerous malignancies including colorectal cancer followed by poor prognosis. The aim of this study is to determine the inhibitory effects of LDD970, an indirubin derivative, on Aurora kinase A in HT29 colorectal cancer cells. In vitro kinase assay revealed that, LDD970 inhibited levels of activated Aurora kinase A (IC50=0.37 mM). The inhibitory effects of LDD970 on Aurora kinase A, autophosphorylation and phosphorylation of histone H3 (Ser10), were confirmed by immunoblot analysis. Moreover, LDD970 inhibited migration of HT29 cells and upregulated apoptosis-related protein cleaved PARP. In cell viability assay, LDD970 was observed to suppress HT29 cell growth (GI50=4.22 µM). Although further studies are required, results of the present study suggest that LDD970 provide a valuable insight into small molecule indirubin derivative for therapeutic potential in human colorectal cancer.
Insights
LDD970, an indirubin derivative, effectively inhibits Aurora kinase A activity in colorectal cancer cells. This compound suppressed cancer cell growth and migration, suggesting therapeutic potential for human colorectal cancer.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Aurora kinase A is crucial for mitosis and its aberrant activity correlates with poor prognosis in colorectal cancer.
- Targeting Aurora kinase A presents a potential therapeutic strategy for colorectal cancer treatment.
Purpose of the Study:
- To investigate the inhibitory effects of LDD970, an indirubin derivative, on Aurora kinase A in HT29 colorectal cancer cells.
- To evaluate the impact of LDD970 on colorectal cancer cell behavior and apoptosis.
Main Methods:
- In vitro kinase assays to determine LDD970's inhibitory concentration (IC50) against Aurora kinase A.
- Immunoblot analysis to assess LDD970's effects on Aurora kinase A autophosphorylation and histone H3 phosphorylation.
- Cell viability, migration, and apoptosis assays (cleaved PARP) to evaluate LDD970's impact on HT29 cells.
Main Results:
- LDD970 demonstrated significant inhibition of activated Aurora kinase A with an IC50 of 0.37 mM.
- LDD970 suppressed HT29 cell growth with a GI50 of 4.22 µM, inhibited cell migration, and upregulated cleaved PARP, indicating apoptosis induction.
- Immunoblotting confirmed LDD970's inhibitory effects on Aurora kinase A, autophosphorylation, and histone H3 phosphorylation.
Conclusions:
- LDD970 exhibits potent inhibitory activity against Aurora kinase A in colorectal cancer cells.
- LDD970 demonstrates anti-proliferative and pro-apoptotic effects on HT29 cells, suggesting its potential as a therapeutic agent.
- Further research into LDD970 as a small molecule indirubin derivative for colorectal cancer treatment is warranted.
